Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 153,400 shares, a growth of 95.4% from the March 31st total of 78,500 shares. Based on an average daily trading volume, of 648,100 shares, the short-interest ratio is presently 0.2 days.
Avalo Therapeutics Stock Performance
AVTX traded up $1.00 on Friday, reaching $15.98. The company had a trading volume of 73,802 shares, compared to its average volume of 537,467. Avalo Therapeutics has a fifty-two week low of $3.95 and a fifty-two week high of $1,130.40. The stock has a market cap of $16.46 million, a P/E ratio of -0.03 and a beta of 1.15. The company’s fifty day moving average is $9.19 and its 200 day moving average is $13.46.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Avalo Therapeutics stock. Acadian Asset Management LLC acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 283,306 shares of the company’s stock, valued at approximately $34,000. Acadian Asset Management LLC owned 1.40% of Avalo Therapeutics as of its most recent SEC filing. 87.06% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Get Our Latest Report on Avalo Therapeutics
About Avalo Therapeutics
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.
Featured Stories
- Five stocks we like better than Avalo Therapeutics
- What is a Dividend King?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is a Secondary Public Offering? What Investors Need to Know
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Investors Need to Know to Beat the Market
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.